降压药物在妊娠期高血压疾病中应用的争议与发展

The controversy and development of antihypertensive agents using for the hypertensive disorders of pregnancy

妊娠期高血压疾病(hypertensive disorders of pregnancy,HDP)是产科最重要合并症之一,严重影响母婴健康。然而,何时采用降压治疗、如何正确应用降压药物在HDP的治疗中始终存在争议,并在争议中不断发展。循证医学显示,肼苯哒嗪和硝苯地平已不再是HDP降压治疗的一线药物,而拉贝洛尔、尼卡地平也许是更好的选择。

Hypertensive disorders of pregnancies remain a most important part of pregnancy complications, which seriously affect both mothers and fetus. However when to use and how antihypertensive agents to use have remained controversial and developable. Evidence based analysis showed that Hydralazine and Nifedipine were no longer the first choice, but Labetalol and Nicardipine may be a good choice.